arrow
M

Marta Morawska

Medical University of Lublin
H指数:15
被引数:850

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Predicted microbiome-associated metabolic pathways are linked to immune checkpoint modulation in chronic lymphocytic leukaemia

预测的微生物组相关代谢通路与慢性淋巴细胞白血病的免疫检查点调节相关

2026-09-070
OAAI
Corrigendum to “Obinutuzumab induction and maintenance in patients with Waldenström macroglobulinaemia: an open-label, single-arm phase 2 study” EClinicalMedicine. 2025 Jul 25:86:103383

勘误:“Obinutuzumab诱导及维持治疗华氏巨球蛋白血症患者的疗效:一项开放标签、单臂II期研究” EClinicalMedicine. 2025年7月25日:86:103383

2026-04-090
OAAI
Daratumumab or active observation for asymptomatic biochemical relapse in patients with multiple myeloma
2026-02-011
PRE
Obinutuzumab induction and maintenance in patients with Waldenström macroglobulinaemia: an open-label, single-arm phase 2 study

奥比妥珠单抗诱导和维持治疗华氏巨球蛋白血症患者的疗效:一项开放标签、单臂2期研究

2025-07-250
OA
Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL

慢性淋巴细胞白血病患者的治疗策略和治疗顺序: 欧洲CLL研究计划ERIC的国际研究

2024-09-170
OAAI
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY

CLL历史上的其他恶性肿瘤: ERIC进行的一项国际多中心研究,欧洲CLL研究倡议,和谐

2023-11-016
OAAI
The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL

慢性淋巴细胞白血病患者新型冠状病毒肺炎和COVID后病情的演变: 欧洲CLL研究计划ERIC的一项研究

2023-09-2911
OAAI
Clinical efficacy and tolerability of venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia-a real-world analysis of the Polish Adult Leukemia Study Group

venetoclax加利妥昔单抗在复发性或难治性慢性淋巴细胞白血病患者中的临床疗效和耐受性-波兰成人白血病研究组的真实世界分析

2023-07-016
OAAI
A Stepwise Screening Protocol for Multiple Myeloma

多发性骨髓瘤的逐步筛查方案

2023-02-082
OAAI
Molnupiravir is effective in patients with haematological malignancies

Molnupiravir对血液系统恶性肿瘤患者有效

2023-02-077
PRE
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL

慢性淋巴细胞白血病和严重新型冠状病毒肺炎患者的血栓和出血并发症: 欧洲CLL研究计划ERIC的研究

2022-08-268
OAAI
Bendamustine-Based Regimens as Salvage Therapy in Refractory/Relapsed Multiple Myeloma Patients: A Retrospective Real-Life Analysis by the Polish Myeloma Group

基于苯达莫司汀的方案作为难治性/复发性多发性骨髓瘤患者的挽救治疗: 波兰骨髓瘤组的回顾性现实分析

2021-11-243
OAAI
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

CLL患者的新型冠状病毒肺炎严重程度和死亡率: 国际ERIC和CLL研究的最新进展

LEUKEMIA
IF13.4
2021-11-0169
OAAI
Endothelial Activation and Stress Index (EASIX) as an Early Predictor for Mortality and Overall Survival in Hematological and Non-Hematological Patients with COVID-19: Multicenter Cohort Study

内皮激活和应激指数 (EASIX) 可作为血液学和非血液学新型冠状病毒肺炎患者死亡率和总生存率的早期预测指标: 多中心队列研究

2021-09-2417
OAAI
Differential Function of a Novel Population of the CD19+CD24hiCD38hi Bregs in Psoriasis and Multiple Myeloma

银屑病和多发性骨髓瘤中CD19 CD24hiCD38hi Bregs的新型人群的差异功能

CELLS
IF5.2
2021-02-1612
OAAI
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group

临床试验以外的慢性淋巴细胞白血病奥比妥珠单抗 ± 氯霉素联合一线治疗: ERIC和以色列CLL研究组的多国多中心研究结果

2020-03-1412
OAAI
Efficacy and safety of obinutuzumab-chlorambucil combination in the frontline treatment of elderly patients with chronic lymphocytic leukemia and comorbidities Real-life data from Polish Adult Leukemia Group (PALG) analysis

来自波兰成人白血病组 (PALG) 的真实数据分析

2018-07-119
OA